If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.50    -10.00 (-2.50%)
Bid:
385.00
Ask:
400.00
Spread: 15.00 (3.896%)
Market Cap: £187.19m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

CFO succession planning

15 May 2025 07:00

RNS Number : 7165I
Tristel PLC
15 May 2025
 

TRISTEL plc

("Tristel" or the "Company" or the "Group")

 

CFO succession planning

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that Liz Dixon, Chief Financial Officer ("CFO"), has confirmed to the Board her intention to retire from the business on 30 June 2025.

 

A process to appoint a new CFO is well underway and the Board has been pleased with the quality of candidates showing an interest in the position. A further announcement will be made in due course.

 

Bruno Holthof, Chair of the Tristel Board, commented: "On behalf of the Company I would like to offer my thanks to Liz for her contribution to the business over the years. Liz has been involved with Tristel since July 2007 when she joined as Group Chief Accountant, before becoming Finance Director of our main trading subsidiary in August 2009, and ultimately joining the Board in June 2010. She played a critical role in securing market access to North America and has positioned Tristel very well for continued profitable growth."

 

Matt Sassone, Chief Executive Officer of Tristel, commented: "Since Liz joined Tristel, the company has grown considerably, and Liz has played a pivotal role in that success. In addition to supporting the operational side of the business, she has been instrumental in driving our commercial performance and built a robust, capable finance team-ensuring we are well-positioned for the continued expansion we anticipate in the years ahead.

 

"It has been a pleasure to work with Liz over the last nine months, and I am grateful that due to her stewardship I have joined a business with a very strong financial position, and well-funded to deliver further organic commercial growth."

 

Liz Dixon, Chief Financial Officer of Tristel, commented: "Whilst I am very sad to be leaving Tristel after nearly 18 years, I do so happy in the knowledge that the business is well placed both financially and commercially for its next stage of growth under the leadership of Matt and the senior team.

 

"It has been a great pleasure to have been part of an amazing UK success story, and to see Tristel establish a leading position in the global infection prevention world. I wish the incredible Tristel team the very best and am confident that they will continue to deliver to our shareholders."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Alice Woodings 

Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFFREIISLIE
Date   Source Headline
8th May 20189:51 amRNSIssue of Equity
2nd May 20184:55 pmRNSDirector/PDMR Dealing and Issue of Equity
23rd Apr 20187:00 amRNSEPA approval received
13th Apr 20182:55 pmRNSIssue of Equity
27th Mar 20188:19 amRNSIssue of Equity
26th Mar 20187:00 amRNSCommercial collaboration with Parker Laboratories
8th Mar 201810:58 amRNSIssue of Equity
20th Feb 20187:00 amRNSHalf-year Report
8th Feb 20182:19 pmRNSHolding(s) in Company
26th Jan 20187:00 amRNSIssue of Equity
24th Jan 20187:00 amRNSStudy shows comparable efficacy of Tristel Wipes
17th Jan 20187:00 amRNSInvestor results presentation
12th Dec 20172:57 pmRNSResult of AGM
12th Dec 20177:00 amRNSAGM Statement & notice of results
27th Nov 201710:35 amRNSIssue of Equity
23rd Nov 20173:24 pmRNSClarification of AGM timing
14th Nov 201710:34 amRNSIssue of Equity
2nd Nov 20177:00 amRNSDirectors dealing/grant of options
23rd Oct 20174:41 pmRNSIssue of Equity
19th Oct 20177:01 amRNSDirector Appointment
19th Oct 20177:00 amRNSFinal Results
3rd Oct 20177:00 amRNSTiming of EPA approval
19th Sep 20177:00 amRNSInvestor results presentation
18th Sep 20171:44 pmRNSIssue of Equity
22nd Aug 201712:08 pmRNSIssue of Equity
18th Aug 20171:31 pmRNSDirector/PDMR Dealing - replacement
17th Aug 20177:00 amRNSDirector/PDMR Dealing
7th Aug 20172:29 pmRNSIssue of Equity
24th Jul 20179:46 amRNSIssue of Equity
19th Jul 20177:00 amRNSTrading update & Notice of results
5th Jul 20177:00 amRNSIssue of Equity
3rd Jul 20171:59 pmRNSStrategic investment
3rd Jul 20177:00 amRNSSubmission to EPA & subsidiary incorporated in USA
13th Jun 20177:00 amRNSIssue of Equity
24th May 20177:00 amRNSShareholder Open Day & Notice of Trading Update
19th May 20173:34 pmRNSIssue of Equity
3rd May 20178:27 amRNSIssue of Equity
7th Apr 20175:04 pmRNSResult of Placing
7th Apr 20172:07 pmRNSProposed Secondary Placing
28th Mar 20172:38 pmRNSIssue of Equity
7th Mar 20179:41 amRNSIssue of Equity
6th Mar 20177:00 amRNSIssue of Equity
27th Feb 20177:00 amRNSProducts approved by Australia's TGA
27th Feb 20177:00 amRNSJournal of Ultrasound in Medicine & Biology
23rd Feb 20177:00 amRNSHalf-year Report
25th Jan 20177:00 amRNSInvestor results presentation
24th Jan 20177:00 amRNSJournal of Infection Prevention: TSTL wipes study
17th Jan 201712:31 pmRNSDirector / PDMR Shareholding
13th Dec 201612:30 pmRNSResult of AGM
13th Dec 20167:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.